$MGTX News

RBC Capital Maintains Outperform on MeiraGTx Holdings, Raises Price Target to $25

MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

MeiraGTx Holdings (NASDAQ:MGTX) Passes Minervini Trend Template and High Growth Momentum Screen

MeiraGTx Hldgs Q1 EPS $(0.57) Misses $(0.44) Estimate, Sales $293.000K Miss $13.913M Estimate

Miami International, Nathan’s Famous, and 3 More Stocks See Action From Activist Investors

OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead

Piper Sandler Maintains Overweight on MeiraGTx Holdings, Raises Price Target to $30

MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?

Evercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector Revisions

RBC Capital Maintains Outperform on MeiraGTx Holdings, Raises Price Target to $24

MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript

MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity - Slideshow

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

MeiraGTx Holdings shares are trading lower after the company announced the pricing of its $100 million offering of 11,111,111 shares at $9 per share. Also, the company entered into an asset purchase agreement with Johnson & Johnson to acquire all interests in bota-vec for the treatment of XLRP.

MeiraGTx Holdings shares are trading lower after the company announced the pricing of its $100 million offering of 11,111,111 shares at $9 per share. Also, the company entered into an asset purchase agreement with Johnson & Johnson to acquire all interests in bota-vec for the treatment of XLRP.

MeiraGTx Holdings Prices Underwritten Offering Of 11,111,111 Of Its Ordinary Shares At $9/Shr; Gross Proceeds Expected To Be ~$100M

MeiraGTx Enters Into Asset Purchase Agreement With Johnson & Johnson To Buy All Interests In Bota-Vec For Treatment Of XLRP; MeiraGTx To Pay J&J $25M Upfront, Milestone Fees, High Double‑Digit Royalties On Bota‑Vec Sales

MeiraGTx's Three-Year Data From Completed Phase 1 AQUAx Study Of AAV-hAQP1 For Grade 2/3 Late Radiation-Induced Xerostomia Shows Meaningful Improvements In Symptoms

MeiraGTx: Turning Dry Mouth Into Liquid Gold